A Study of Dulaglutide in Japanese Participants With Type 2 Diabetes Mellitus

NCT01584232 · Completed

Last updated 2026-05-28

This clinical trial tested the medication dulaglutide in Japanese adults with type 2 diabetes to see how it affects blood sugar levels over 26 weeks.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 361 people

Who can join Ages 20+ · all sexes

Timeline Started 2012-04 · est. completion 2013-07

Where 15 sites · Japan

What this study is testing ClinicalTrials.gov NCT01584232 ↗

Description as written by the study sponsor.

The purpose of this trial is to examine the efficacy and safety of once-weekly LY2189265 (dulaglutide) in participants with type 2 diabetes mellitus taking an oral antihyperglycemic medication (OAM).

Treatments tested

LY2189265 also known as Dulaglutide Drug
Insulin glargine Drug
Sulfonylureas (SU) Drug
Biguanide (BG) Drug

Main thing measured	Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 26 Weeks
Sponsor	Eli Lilly and Company
Conditions studied	Type 2 Diabetes Mellitus
GLP-1 drugs	dulaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01584232 ↗